ABBVIE INC.

ISIN: US00287Y1091 WKN: 00287Y109 Asset Class: Stock



Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures		Liabilities and equity		Liabilities and equity		iabilities and equity
Current assets	33,002,000,000		28,463,000,000		27,928,000,000	
Common stock capital		18,000,000		18,000,000		18,000,000
Fixed assets	101,709,000,000		110,342,000,000		118,601,000,000	
Equity capital of a company		10,397,000,000		17,287,000,000		15,436,000,000
Cash and cash equivalents	12,814,000,000		9,201,000,000		9,746,000,000	
Accrued liabilities		1,538,000,000		1,638,000,000		3,153,000,000
Other assets	-		-		-	
Current liabilities		37,841,000,000		29,538,000,000		35,194,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		86,473,000,000		91,980,000,000		95,899,000,000
Different income		-		-		-
Other liabilities		23,373,000,000		21,761,000,000		18,865,000,000
Total assets	134,711,000,000	134,711,000,000	138,805,000,000	138,805,000,000	146,529,000,000	146,529,000,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	50,000	50,000	50,000
Equity ratio	7.75%	12.48%	10.55%
Debt-equity ratio	1,191.08%	701.41%	847.55%

Others

	2023	2022	2021
Tax Expense Rate	22.03%	12.11%	11.09%

ABBVIE INC.

ISIN: US00287Y1091 WKN: 00287Y109 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	54,318,000,000	58,054,000,000	56,197,000,000
Net income	4,820,000,000	11,782,000,000	11,468,000,000
EBIT	7,451,031,000	14,437,642,100	14,217,896,700
Operating income before taxes	6,250,000,000	13,477,000,000	12,989,000,000
Cash Flow	22,801,000,000	24,943,000,000	22,777,000,000
Net interest income	-1,820,000,000	-2,160,000,000	-2,410,000,000
Research and development expenses	7,038,000,000	6,487,000,000	6,980,000,000
Income taxes	1,377,000,000	1,632,000,000	1,440,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	1,003,036	1,072,025	1,037,734

Board of Directors

Members of Management Board		
Robert Alpern	Member of Board of Directors	
Susan Quaggin	Member of Board of Directors	
Brett Hart	Member of Board of Directors	
Edward Rapp	Member of Board of Directors	
Frederick Waddell	Member of Board of Directors	
Glenn Tilton	Member of Board of Directors	
Jennifer Davis	Member of Board of Directors	
Melody Meyer	Member of Board of Directors	
Rebecca Roberts	Member of Board of Directors	
Roxanne Austin	Member of Board of Directors	
Thomas Freyman	Member of Board of Directors	
William Burnside	Member of Board of Directors	
Richard A. Gonzalez	Chairman of Managing Board	
Azita Saleki-Gerhardt	Member of Executive Committee	
Jeffrey R. Stewart	Member of Executive Committee	
Nicholas Donoghoe	Member of Executive Committee	
Perry C. Siatis	Member of Executive Committee	
Robert A. Michael	Member of Executive Committee	
Scott Reents	Member of Executive Committee	
Timothy J. Richmond	Member of Executive Committee	